T1	Participants 49 97	during prescription opioid dependence treatment.
T2	Participants 468 478	outpatient
T3	Participants 559 710	participants with prescription opioid dependence who received 12 weeks of buprenorphine-naloxone and counseling in a multi-site clinical trial (N=353).
T4	Participants 1548 1595	individuals with prescription opioid addiction.
